Piper Sandler Maintains Neutral on ImmunityBio, Lowers Price Target to $4.75
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains a Neutral rating on ImmunityBio (NASDAQ:IBRX) and lowers the price target from $6 to $4.75.
August 19, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on ImmunityBio and reduced the price target from $6 to $4.75, indicating a less optimistic outlook.
The reduction in price target from $6 to $4.75 by Piper Sandler suggests a less favorable view on ImmunityBio's near-term prospects, which could lead to downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100